U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Epithelioid Mesothelioma

MedGen UID:
1782245
•Concept ID:
C5446866
•
Neoplastic Process

Definition

The reemergence of epithelioid mesothelioma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Epithelioid Mesothelioma

Professional guidelines

PubMed

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.
Giger-Pabst U, Demtröder C, Falkenstein TA, Ouaissi M, Götze TO, Rezniczek GA, Tempfer CB
BMC Cancer 2018 Apr 18;18(1):442. doi: 10.1186/s12885-018-4363-0. PMID: 29669524Free PMC Article
Vulvar sarcomas: Short guideline for histopathological recognition and clinical management. Part 2.
Chokoeva AA, Tchernev G, Cardoso JC, Patterson JW, Dechev I, Valkanov S, Zanardelli M, Lotti T, Wollina U
Int J Immunopathol Pharmacol 2015 Jun;28(2):178-86. Epub 2015 Mar 26 doi: 10.1177/0394632015575977. PMID: 25816393
Pathohistological diagnosis and differential diagnosis.
Tischoff I, Neid M, Neumann V, Tannapfel A
Recent Results Cancer Res 2011;189:57-78. doi: 10.1007/978-3-642-10862-4_5. PMID: 21479896

Recent clinical studies

Etiology

Expanding the clinicopathologic spectrum and genomic landscape of tumors with SMARCA2/4::CREM fusions.
Cyrta J, Dermawan JK, Tauziède-Espariat A, Liu T, Rosenblum M, Shroff S, Katabi N, Cardoen L, Guillemot D, Masliah-Planchon J, Hoare O, Delattre O, Bale T, Bourdeaut F, Antonescu CR
J Pathol 2024 Nov;264(3):305-317. Epub 2024 Sep 30 doi: 10.1002/path.6350. PMID: 39344423
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators
Lancet Oncol 2021 Nov;22(11):1530-1540. Epub 2021 Oct 14 doi: 10.1016/S1470-2045(21)00471-X. PMID: 34656227Free PMC Article
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup
Lancet Oncol 2019 Feb;20(2):239-253. Epub 2019 Jan 16 doi: 10.1016/S1470-2045(18)30765-4. PMID: 30660609
Malignant pleural mesothelioma in Singapore.
Yip CS, Koong HN, Loo CM, Fong KW
Asian Pac J Cancer Prev 2011;12(5):1155-9. PMID: 21875258

Diagnosis

New developments in mesothelial pathology.
Churg A
Histopathology 2024 Jan;84(1):136-152. Epub 2023 Sep 11 doi: 10.1111/his.15007. PMID: 37694811
Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma.
Schaefer IM, Mariño-Enríquez A, Hammer MM, Padera RF, Sholl LM
Mod Pathol 2023 Sep;36(9):100237. Epub 2023 Jun 8 doi: 10.1016/j.modpat.2023.100237. PMID: 37295554Free PMC Article
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI, Tjota MY, Gao G, Mitchell O, Kindler H, Segal J, Husain AN, Mueller J, Schulte JJ
Am J Clin Pathol 2023 Sep 1;160(3):238-246. doi: 10.1093/ajcp/aqad041. PMID: 37141416
Malignant pleural mesothelioma in Singapore.
Yip CS, Koong HN, Loo CM, Fong KW
Asian Pac J Cancer Prev 2011;12(5):1155-9. PMID: 21875258
Pathohistological diagnosis and differential diagnosis.
Tischoff I, Neid M, Neumann V, Tannapfel A
Recent Results Cancer Res 2011;189:57-78. doi: 10.1007/978-3-642-10862-4_5. PMID: 21479896

Therapy

Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial.
Dietz MV, Quintelier KLA, van Kooten JP, de Boer NL, Vink M, Brandt-Kerkhof ARM, Verhoef C, Saeys Y, Aerts JGJV, Willemsen M, Van Gassen S, Madsen EVE
J Immunother Cancer 2023 Aug;11(8) doi: 10.1136/jitc-2023-007070. PMID: 37536940Free PMC Article
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators
Lancet Oncol 2021 Nov;22(11):1530-1540. Epub 2021 Oct 14 doi: 10.1016/S1470-2045(21)00471-X. PMID: 34656227Free PMC Article
Multicystic and diffuse malignant peritoneal mesothelioma in children.
Vermersch S, Arnaud A, Orbach D, Andre N, Berger C, Kepenekian V, Brigand C, Fresneau B, Poli-Merol ML, Habougit C, Varlet F, Scalabre A
Pediatr Blood Cancer 2020 Jun;67(6):e28286. Epub 2020 Apr 11 doi: 10.1002/pbc.28286. PMID: 32277799
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup
Lancet Oncol 2019 Feb;20(2):239-253. Epub 2019 Jan 16 doi: 10.1016/S1470-2045(18)30765-4. PMID: 30660609

Prognosis

Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms.
Benzerdjeb N, Dartigues P, Kepenekian V, Damiola F, Sequeiros R, Galateau-Salle F, Begueret H, Mery E, Damotte D, Verriele V, Fontaine J, Isaac S, Valmary-Degano S, Villeneuve L, Glehen O, Scherpereel A, Forest F, De la Fourchardiere A, Paindavoine S, Hourlier A, Pissaloux D, Tirode F, Lantuejoul S; RENAPE and the NETMESO/MESOPATH Networks
ESMO Open 2024 Aug;9(8):103644. Epub 2024 Jul 25 doi: 10.1016/j.esmoop.2024.103644. PMID: 39059063Free PMC Article
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI, Tjota MY, Gao G, Mitchell O, Kindler H, Segal J, Husain AN, Mueller J, Schulte JJ
Am J Clin Pathol 2023 Sep 1;160(3):238-246. doi: 10.1093/ajcp/aqad041. PMID: 37141416
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators
Lancet Oncol 2021 Nov;22(11):1530-1540. Epub 2021 Oct 14 doi: 10.1016/S1470-2045(21)00471-X. PMID: 34656227Free PMC Article
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Pathohistological diagnosis and differential diagnosis.
Tischoff I, Neid M, Neumann V, Tannapfel A
Recent Results Cancer Res 2011;189:57-78. doi: 10.1007/978-3-642-10862-4_5. PMID: 21479896

Clinical prediction guides

Circulating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma.
Paajanen J, Sadek A, Richards WG, Xie Y, Mazzola E, Sidopoulos K, Kuckelman J, Gill RR, Bueno R
Thorac Cancer 2024 May;15(15):1237-1245. Epub 2024 Apr 16 doi: 10.1111/1759-7714.15264. PMID: 38627917Free PMC Article
New developments in mesothelial pathology.
Churg A
Histopathology 2024 Jan;84(1):136-152. Epub 2023 Sep 11 doi: 10.1111/his.15007. PMID: 37694811
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI, Tjota MY, Gao G, Mitchell O, Kindler H, Segal J, Husain AN, Mueller J, Schulte JJ
Am J Clin Pathol 2023 Sep 1;160(3):238-246. doi: 10.1093/ajcp/aqad041. PMID: 37141416
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, Sciaranghella D, Dao N, Gustafson CE, Munir KJ, Hackney JA, Chaudhuri A, Gupta R, Guillory J, Toy K, Ha C, Chen YJ, Stinson J, Chaudhuri S, Zhang N, Wu TD, Sugarbaker DJ, de Sauvage FJ, Richards WG, Seshagiri S
Nat Genet 2016 Apr;48(4):407-16. Epub 2016 Feb 29 doi: 10.1038/ng.3520. PMID: 26928227

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...